Linna Wang
Impact in
- Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
Papers in
- Oncology 9
- Colorectal Cancer Treatments and Studies 3
- Cancer Immunotherapy and Biomarkers 2
-
- Neurological Disease Mechanisms and Treatments 5
- Co-authors
- Jianjun Zou (9 shared papers)Shukui Qin (5 shared papers)Jianping Xiong (6 shared papers)Zhiqiang Meng (5 shared papers)Zhendong Chen (2 shared papers)Zhenggang Ren (4 shared papers)Yuxian Bai (3 shared papers)Weijia Fang (3 shared papers)
- Journals
- Journal of Clinical Oncology (5 papers)Clinical Cancer Research (2 papers)Biomedicine & Pharmacotherapy (2 papers)The Journal of Physical Chemistry B (1 paper)Journal of Medicinal Chemistry (1 paper)
- Partner nations
- ChinaRomaniaUnited States
In The Last Decade
Linna Wang
32 papers receiving 1.2k citations
Linna Wang's Hit Papers
Peers
Comparison fields: 5 of 102
- Hepatology 331
- Oncology 411
- Pathology and Forensic Medicine 144
- Neurology 68
- Immunology 137
Countries citing papers authored by Linna Wang
This map shows the geographic impact of Linna Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linna Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linna Wang more than expected).
Fields of papers citing papers by Linna Wang
This network shows the impact of papers produced by Linna Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linna Wang. The network helps show where Linna Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Linna Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 32 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial Hit paper breakdown → | 2020 | 431 |
| 2 | 2020 | 98 | |
| 3 | 2021 | 79 | |
| 4 | 2021 | 62 | |
| 5 | 2019 | 56 | |
| 6 | 2015 | 54 | |
| 7 | 2023 | 52 | |
| 8 | 2022 | 46 | |
| 9 | 2021 | 39 | |
| 10 | 2013 | 38 | |
| 11 | 2018 | 33 | |
| 12 | 2021 | 27 | |
| 13 | 2013 | 19 | |
| 14 | 2017 | 18 | |
| 15 | 2021 | 17 | |
| 16 | 2021 | 16 | |
| 17 | 2023 | 15 | |
| 18 | 2024 | 14 | |
| 19 | 2021 | 13 | |
| 20 | 2019 | 11 |
About Linna Wang
Linna Wang is a scholar working on Oncology, Neurology, Surgery, Pulmonary and Respiratory Medicine and Hepatology, having authored 32 papers that have together received 1.2k indexed citations. Recurring topics across this work include Neurological Disease Mechanisms and Treatments (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers), Colorectal Cancer Treatments and Studies (3 papers), Cancer Research and Treatments (3 papers), Chronic Kidney Disease and Diabetes (2 papers), Advanced Glycation End Products research (2 papers), Cancer Immunotherapy and Biomarkers (2 papers) and Traditional Chinese Medicine Analysis (2 papers). The work is most often cited by research in Hepatology (331 citations), Oncology (411 citations), Pathology and Forensic Medicine (144 citations), Neurology (68 citations) and Immunology (137 citations). Linna Wang has collaborated with scholars based in China, Romania and United States. Frequent co-authors include Jianjun Zou, Shukui Qin, Jianping Xiong, Zhiqiang Meng, Zhendong Chen, Zhenggang Ren, Yuxian Bai, Weijia Fang, Xiaoli Chai and Enxiao Li. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Biomedicine & Pharmacotherapy, The Journal of Physical Chemistry B and Journal of Medicinal Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.